Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,657 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
Brave SR, Odedra R, James NH, Smith NR, Marshall GB, Acheson KL, Baker D, Howard Z, Jackson L, Ratcliffe K, Wainwright A, Lovick SC, Hickinson DM, Wilkinson RW, Barry ST, Speake G, Ryan AJ. Brave SR, et al. Among authors: baker d. Int J Oncol. 2011 Jul;39(1):271-8. doi: 10.3892/ijo.2011.1022. Epub 2011 Apr 29. Int J Oncol. 2011. PMID: 21537841
Tumor stromal phenotypes define VEGF sensitivity--response.
Smith NR, Baker D, Farren M, Pommier A, Swann R, Wang X, Mistry S, McDaid K, Kendrew J, Womack C, Wedge SR, Barry ST. Smith NR, et al. Among authors: baker d. Clin Cancer Res. 2014 Oct 1;20(19):5141. doi: 10.1158/1078-0432.CCR-14-0681. Clin Cancer Res. 2014. PMID: 25274380 No abstract available.
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer.
Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, Kayani I, Bex A, Wan E, O'Mahony FC, O'Donnell M, Chowdhury S, Doshi R, Ho-Yen C, Gerlinger M, Baker D, Smith N, Davies B, Sahdev A, Boleti E, De Meyer T, Van Criekinge W, Beltran L, Lu YJ, Harrison DJ, Reynolds AR, Powles T. Sharpe K, et al. Among authors: baker d. Clin Cancer Res. 2013 Dec 15;19(24):6924-34. doi: 10.1158/1078-0432.CCR-13-1631. Epub 2013 Oct 15. Clin Cancer Res. 2013. PMID: 24130073 Clinical Trial.
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.
Jenkins DW, Ross S, Veldman-Jones M, Foltz IN, Clavette BC, Manchulenko K, Eberlein C, Kendrew J, Petteruti P, Cho S, Damschroder M, Peng L, Baker D, Smith NR, Weir HM, Blakey DC, Bedian V, Barry ST. Jenkins DW, et al. Among authors: baker d. Mol Cancer Ther. 2012 Aug;11(8):1650-60. doi: 10.1158/1535-7163.MCT-11-1027. Epub 2012 Jun 7. Mol Cancer Ther. 2012. PMID: 22679110
Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon.
Rooney C, Geh C, Williams V, Heuckmann JM, Menon R, Schneider P, Al-Kadhimi K, Dymond M, Smith NR, Baker D, French T, Smith PD, Harrington EA, Barrett JC, Kilgour E. Rooney C, et al. Among authors: baker d. PLoS One. 2016 Feb 23;11(2):e0149628. doi: 10.1371/journal.pone.0149628. eCollection 2016. PLoS One. 2016. PMID: 26905262 Free PMC article.
5,657 results